Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTNFCQ)

• Drug Name: Levobunolol Drug Info
• Synonyms: Akbeta; Betagan; Levobunololum; Levobunolol HCl; Betegan (TN); Levobunolol (INN); Levobunolol [INN:BAN]; Levobunololum [INN-Latin]; Liquifilm (TN); W-6412A; W-7000A; AK-Beta (TN); (-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one
• Therapeutic Class: Sympatholytics
• Cross-matching ID:
  PubChem CID: 39468
  ChEBI ID: CHEMBL1201237
  CAS Number: CAS 47141-42-4
  TTD Drug ID: D00IUG
  INTEDE Drug ID: DR0933

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Hematopoietic cell lineage	-1.68	3.92e-2	90/99 (90.91%)	HLA-DPB1;GP9;FLT3;...
Autoimmune thyroid disease	-1.73	2.42e-2	46/53 (86.79%)	HLA-DRB1;CD28;HLA-B;...
Steroid hormone biosynthesis	-1.76	2.10e-2	43/61 (70.49%)	AKR1C4;CYP3A7;CYP21A2;...
Viral myocarditis	-1.76	2.26e-2	53/60 (88.33%)	ICAM1;HLA-DPB1;HLA-DRA;...
Folate biosynthesis	-1.76	2.12e-2	23/26 (88.46%)	PTS;SPR;MOCOS;...
Drug metabolism	-1.77	2.23e-2	78/151 (51.66%)	XDH;FMO5;GMPS;...
Pertussis	-1.85	8.81e-3	64/76 (84.21%)	IL1A;IL6;RELA;...
Allograft rejection	-1.87	8.70e-3	32/38 (84.21%)	HLA-DRB1;CD28;HLA-B;...
Cytosolic DNA-sensing pathway	-1.89	7.34e-3	52/63 (82.54%)	IFNB1;POLR3K;IL6;...
Glutathione metabolism	-1.93	6.99e-3	43/57 (75.44%)	GPX4;IDH1;GSTM1;...
Non-alcoholic fatty liver disease	-1.94	6.53e-3	126/155 (81.29%)	NDUFS3;PPARG;NDUFA1;...
Oxidative phosphorylation	-2.04	0.00e+0	93/133 (69.92%)	SDHC;TCIRG1;NDUFA9;...
Staphylococcus aureus infection	-2.10	0.00e+0	72/95 (75.79%)	HLA-DQB1;MBL2;PLG;...
Complement and coagulation cascades	-2.14	0.00e+0	76/85 (89.41%)	F8;F13B;C8G;...
Graft-versus-host disease	-2.27	0.00e+0	32/42 (76.19%)	KLRD1;CD80;KIR2DL3;...
Metabolism of xenobiotics by cytochrome P450	-2.44	0.00e+0	49/77 (63.64%)	HSD11B1;CYP2A6;CYP3A4;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	6.66uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼